Throughout the 1990s, Amgen continued in the same vein, investing heavily in R&,D, expanding its sales and bringing out new medications such as Infergen, an anti-hepatitis C medication ...
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 19 unusual trades. Delving into the details, we found 26% of traders were ...
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $314.38.
Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...
Xtrackers S&P 500 Swap UCITS ETF - 1C USD ACC 23% SPDR S&P 500 UCITS ETF - USD DIS 23% ...
Pre-Market: 8:59:48 a.m. EDT Loading Chart for AMGN ...
After hours: 21 March at 7:58:05 pm GMT-4 Loading Chart for AMGN ...
After hours: 24 March at 19:42:09 GMT-4 Loading Chart for AMGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback